Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211970 | 0.67 | LAP3 (0.40) | LAP3FDPSLMNA | |
| SCHEMBL27783191 | 0.67 | FDPS (0.40) | LAP3FDPSLMNAGRM4 | |
| SCHEMBL5887949 | 0.66 | — | — | |
| SCHEMBL98484 | 0.66 | LMNA (0.39) | LAP3FDPSLMNA | |
| SCHEMBL6633665 | 0.64 | LAP3 (0.34) | LAP3FDPS | |
| SCHEMBL29155304 | 0.64 | FDPS (0.36) | LAP3FDPSLMNA | |
| SCHEMBL11719735 | 0.62 | — | — | |
| SCHEMBL11151927 | 0.62 | FDPS (0.34) | LAP3FDPSLMNA | |
| SCHEMBL20606628 | 0.62 | LAP3 (0.31) | LAP3FDPSLMNA | |
| SCHEMBL8522272 | 0.62 | LAP3 (0.41) | LAP3FDPSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060115815-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | CCNI, INTS6, CCNE1 | LAP3 2239/4885FDPS 2945/4885LMNA 30/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | LAP3 2231/4885FDPS 2502/4885LMNA 24/4885 |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | LAP3 1817/4885FDPS 2916/4885LMNA 17/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | LAP3 185/4885FDPS 504/4885LMNA 2684/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | LAP3 222/4885FDPS 476/4885LMNA 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.